ABSTRACT
(1-4) Although, worldwide, vitamin D deficiency is the principal cause of rickets, in some countries, such as Nigeria and Bangladesh, nutritional rickets results primarily from inadequate calcium intake. (5, 6) Untreated Nigerian children with nutritional rickets have normal or only slightly reduced 25(OH)D values, (7) high fractional calcium absorption, (8) low dietary calcium intake, (7) markedly elevated 1,25(OH) 2 D concentrations, and a better response to treatment with calcium than with vitamin D. (9) These findings indicate that dietary calcium deficiency plays a more important role in the pathogenesis of rickets in Nigerian children than does vitamin D deficiency. Operationally, vitamin D sufficiency represents a state in which the serum concentration of 1,25(OH) 2 D will not increase further after raising the concentration of 25(OH)D. Under these conditions, serum levels of substrate 25(OH)D are adequate to maintain the required 1,25(OH) 2 D concentrations. (10, 11) Moreover, the concentration of 25(OH)D necessary to ensure normal mineral homeostasis will depend on the usual intake of dietary calcium. Not surprisingly, Nigerian children with rickets owing to dietary calcium deficiency have evidence for an increased requirement for vitamin D to optimize mineral metabolism. (12) Dietary calcium deficiency leads to secondary hyperparathyroidism, which decreases serum levels of 25(OH)D both directly, through increased conversion to 1,25(OH) 2 D, and indirectly, via enhanced degradation of 25(OH)D by the 24-hydroxylase enzyme CYP24A1, which is induced by 1,25(OH) 2 D. (13, 14) Administration of vitamin D 2 to Nigerian children with rickets produces a nearly twofold increase in 1, (17, 18) The aim of this study was to compare the short-term metabolism of vitamin D 2 with that of vitamin D 3 in children with rickets and in healthy control children without rickets.
Materials and Methods
We recruited children with genu varus or valgus deformities characteristic of rickets from the outpatient department of the Jos University Teaching Hospital in Nigeria. Radiographs of the wrists and knees were obtained. Those with active rickets, defined as a radiographic score of 1.5 or greater on a 10-point scale of severity, (19) were invited to participate in the study.
Approval for the study was obtained from the Ethical Committee of the Jos University Teaching Hospital and the Institutional Review Board of the Mayo Clinic, and written informed consent was obtained from a parent of each enrolled child. Healthy control children were recruited by asking each parent of a child with rickets to invite a child without clinical evidence of rickets of the same age and gender, who was a neighbor or relative, to participate. In cases where a neighbor or relative control was unable to be recruited, control children were recruited among the staff of the outpatient department. Transportation costs were paid for all enrolled children, and a gift valued at approximately $10 was provided to each enrolled child. Children with rickets were provided with 6 months of treatment with calcium and vitamin D at no cost after completing the 2-week study. Calcium was withheld during the study to avoid confounding the relationships between biochemical variables, allowing all changes to be attributed to the effect of vitamin D.
Data were collected from all children regarding usual sunlight exposure and the frequency and quantity of dairy product intake. The percentage of unclothed skin at enrollment was estimated by using a Lund and Browder age-related burn chart. Control children were randomly assigned by lottery to receive either vitamin D 3 (cholecalciferol; Bio-Tech, Fayetteville, AR, USA) or vitamin D 2 (ergocalciferol; Pliva, Inc., East Hanover, NJ, USA) as a single oral dose of 1.25 mg (50,000 IU). Although the potency of each form of vitamin D was identical, the matrix materials were not identical for the two products. Venous blood was collected at baseline and at 1, 3, 7, and 14 days after administration of vitamin D. All rachitic children in this study were given a single dose of vitamin D 3 because the data on the metabolism of vitamin D 2 in rickets were obtained from a previous study of 16 Nigerian children with rickets using vitamin D 2 with an identical study protocol and laboratory. (12) Serum samples were transported frozen to the Mayo Clinic for analysis. Serum calcium, phosphorus, alkaline phosphatase, and albumin were measured by standard methods. We measured all vitamin D metabolites by isotope-dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Results
A total of 46 children with lower extremity deformities were screened, and 13 children (4 males, 9 females) with radiographic evidence of rickets were recruited to receive vitamin D 3 . One child with rickets who received vitamin D 3 was excluded from analysis because her response was an extreme outlier (described below). A total of 23 control children were recruited. One control child who received vitamin D 3 did not return after the baseline visit and was excluded from the analysis. A second control child who failed to demonstrate an increase in serum concentration of 25(OH)D after administration of vitamin D 2 was excluded from analysis because of doubts that he actually ingested the dose of vitamin D 2 . Data from 16 previously studied children with active rickets who had received vitamin D 2 using the same protocol were included in the analysis.
Baseline characteristics of enrolled children are shown in 
Age ( Total 25(OH)D concentrations peaked on day 3 (Fig. 1) , and incremental changes were similar in the rachitic children who received vitamin D 2 or vitamin D 3 (29 AE 17 and 25 AE 11 ng/mL, respectively) and in control children after vitamin D 2 or vitamin D 3 administration (33 AE 13 and 31 AE 16 ng/mL, respectively). These data suggest that the bioavailability of both forms of vitamin D was similar despite differences in the matrices of the two preparations and greater levels of serum vitamin D 2 on day 1. The day 3 concentration of total 25(OH)D was less than 30 ng/ mL in 6 (21%) of the children with rickets and in none of the control children. The highest values of 25(OH)D, attained on day 3, were 77 and 101 ng/mL in rachitic and control children, respectively. The disappearance rate of total 25(OH) 30 ng/mL (approximately 0.6 ng/1000 IU of vitamin D) both in children with rickets and in healthy control children. The peak concentration of 25(OH)D that occurred 3 days after vitamin D administration is earlier than that seen in adults (7 days). (21, 22) We surmise that this may be related to a greater activity of hepatic 25-hydroxylase in children compared with adults. Indirect evidence for this is the observation that older adults have a less rapid rise and a slower clearance of 25(OH)D than younger adults.
The serum concentration of 25(OH)D 3 declined gradually after administration of oral gradually D 2 in both healthy control children (33% reduction by day 14) and children with rickets (50% reduction by day 14). In the children with rickets, this effect could be due to both induction of CYP24 by increasing concentrations of 1,25(OH) 2 with rickets does not produce a corresponding increase in fractional calcium absorption (20) probably because intestinal calcium absorption (72%) is already maximal. We propose that primary calcium deficiency in Nigerian children induces an increase in 1a-hydroxylase activity that, combined with increased activity of degradative pathways (eg, CYP24), results in a state of relative vitamin D deficiency. (12) Based on a growing body of evidence, it is likely that reduced serum levels of 25(OH)D have an independent and adverse effect on bone and mineral metabolism in these children, leading both to increased secretion of PTH (23, 24) and impaired bone mineralization. (25) Despite their greater baseline 1,25(OH) 2 D concentrations, rachitic children had lower baseline 24,25(OH) 2 (27) Some of our findings are consistent with more rapid metabolism of vitamin D 2 than vitamin D 3 . One day following vitamin D administration, the concentration of serum vitamin D 2 was lower in control children who received vitamin D 2 than the vitamin D 3 concentration in control children who received vitamin D 3 . At the same time, the 25(OH)D concentration rose more rapidly ( p ¼ .05 for difference in day 1 increment) and was followed by an earlier decline in children with rickets who received vitamin D 2 compared with rachitic children who received vitamin D 3 . In both children with rickets and control children, the concentrations of 24,25(OH) 2 D rose more rapidly and declined earlier after vitamin D 2 administration than after vitamin D 3 administration. More rapid metabolism of vitamin D 2 than vitamin D 3 could reflect lower affinity for vitamin D-binding protein, increased affinity for the 24-hydroxylase CYP24 enzyme, and/or increased affinity for the 1a-hydroxylase CYP27B1.
Our previous study of the response to vitamin D 2 in Nigerian children with rickets was limited by the absence of a control group without rickets. (12) This study thus offers several advantages over our previous work. For example, the findings of this study are strengthened by inclusion of control groups of healthy children, and we were able to compare the responses to vitamin D 2 and vitamin D 3 . However, this report also has several limitations. The children with rickets who received vitamin D 2 were a historical comparison group that was studied with an identical protocol. Consequently, their baseline characteristics differed from rachitic children who received vitamin D 3 , and the laboratory methods for determining vitamin D metabolites were different. However, we were able to demonstrate on stored sera the comparability of laboratory methods. We elected to use the historical vitamin D 2 group of children with rickets because randomly assigning the group with rickets in this study to receive either vitamin D 2 or vitamin D 3 would have resulted in only half the number of children with rickets in each group, which would have resulted in reduced power in an already limited sample size. By using the same methodology and the same laboratory, we could compare the results directly without having to repeat the vitamin D 2 challenge in a group of children with rickets. An additional shortcoming of this report includes the fact that the rachitic children who received vitamin D 2 appeared to be more severely affected than the children who received vitamin D 3 . Finally, the lack of information on PTH concentrations in any of the groups of children makes our interpretation on the possible differences in factors driving CYP27B1 speculative. We conclude that in the short term, vitamins D 2 and D 3 similarly increase 25(OH)D concentrations in rachitic and healthy children. However, vitamin D 2 may be metabolized more rapidly than vitamin D 3 , thus supporting previous recommendations that cholecalciferol be considered the vitamin D of choice for the treatment of rickets. A marked increase in 1,25(OH) 2 D concentration in response to administration of vitamin D distinguishes children with putative dietary calcium-deficiency rickets from healthy children, thus indicating that vitamin D plus calcium should be used together in the treatment of nutritional rickets whether vitamin D or calcium deficiency is the primary etiology.
